CIPRAMIL 10 MG FILM-COATED TABLETS

Main information

  • Trade name:
  • CIPRAMIL 10 MG FILM-COATED TABLETS
  • Dosage:
  • 10 Milligram
  • Pharmaceutical form:
  • Tablets
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CIPRAMIL 10 MG FILM-COATED TABLETS
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PPA0465/068/001A
  • Authorization date:
  • 24-08-2001
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Cipramil10mgFilm-CoatedTablets.

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachfilm-coatedtabletcontainscitalopramhydrobromideequivalentto10mgcitalopram.

Excipients:lactosemonohydrate.

Forfulllistexcipients,seesection6.1

3PHARMACEUTICALFORM

Film-coatedtablet.

Round,whitetabletswith‘CL’embossedononesideandplainontheother.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Treatmentofdepressiveillnessintheinitialphaseandasmaintenanceagainstpotentialrelapse/recurrence.

Cipramilisalsoindicatedinthetreatmentofpanicdisorderwithorwithoutagoraphobia.

4.2Posologyandmethodofadministration

Adults

TreatingDepression

Citalopramshouldbeadministeredasasingleoraldoseof20mgdaily.Dependentonindividualpatientresponseand

severityofdepressionthedosemaybeincreasedtoamaximumof60mgdaily.

TreatingPanicDisorder

Asingleoraldoseof10mgisrecommendedforthefirstweekbeforeincreasingthedoseto20mgdaily.Thedosemay

befurtherincreased,uptoamaximumof60mgdailydependentonindividualpatientresponse.

Elderlypatients(>65yearsofage)

Inelderlypatientsthedosemaybeincreasedtoamaximumof40mgdaily.

Children&Adolescents(<18years)

Cipramilshouldnotbeusedinthetreatmentofchildrenandadolescentsundertheageof18years(seesection4.4

Specialwarningsandprecautionsforuse).

Reducedrenalfunction

Dosageadjustmentisnotnecessaryinpatientswithmildormoderaterenalimpairment.Noinformationisavailableon

treatmentofpatientswithseverelyreducedrenalfunction(creatinineclearance<20ml/min).

Reducedhepaticfunction

Patientswithreducedhepaticfunctionshouldreceivedosagesofnomorethan30mg/day.

MethodofAdministration

Citalopramtabletsareadministeredasasingledailydoseandcanbetakenatanytimeofthedaywithoutregardto

foodintake.

Durationoftreatment

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 1

thereforebecontinuedforanappropriatelengthoftime,usuallyupto6monthsafterrecoveryinordertoprevent

relapse.Inpatientswithrecurrentdepression(unipolar)maintenancetherapymayneedtobecontinuedforanumberof

yearstopreventnewepisodes.

Maximumeffectivenessofcitalopramintreatingpanicdisorderisreachedafterabout3monthsandtheresponseis

maintainedduringcontinuedtreatment.

WithdrawalsymptomsseenondiscontinuationofSSRI.

Abruptdiscontinuationshouldbeavoided.Whenstoppingtreatmentwithcitalopramthedoseshouldbegradually

reducedoveraperiodofatleastoneortwoweeksinordertoreducetheriskofwithdrawalreactions(seesection4.4

andsection4.8).Ifintolerablesymptomsoccurfollowingadecreaseinthedoseorupondiscontinuationoftreatment,

thenresumingthepreviouslyprescribeddosemaybeconsidered.Subsequentlythephysicianmaycontinuedecreasing

thedose,butatamoregradualrate.

4.3Contraindications

Hypersensitivitytotheactivesubstanceortoanyoftheexcipients(seesection6.1).

MAOIs(monoamineoxidaseinhibitors)

CasesofseriousandsometimesfatalreactionshavebeenreportedinpatientsreceivinganSSRIincombinationwith

monoamineoxidaseinhibitor(MAOI),includingtheselectiveMAO-BinhibitorselegilineandthereversibleMAOI

(RIMA),moclobemideandinpatientswhohaverecentlydiscontinuedanSSRIandhavebeenstartedonaMAOI.

Somecasespresentedwithfeaturesresemblingserotoninsyndrome.

CitaloprammustnotbeusedincombinationwithaMAOIincludingselegilineindosesabove10mgdaily.

Treatmentwithcitaloprammaybeinstituted14daysafterdiscontinuationofnon-selectiveMAOIsandminimumone

dayafterdiscontinuationofmoclobemide.TreatmentwithMAOIsmaybeintroduced7daysafterdiscontinuationof

citalopram(seesection4.5Interactionwithothermedicinalproductsandotherformsofinteraction).

Concomitanttreatmentwithpimozide.

4.4Specialwarningsandprecautionsforuse

Treatmentofelderlypatientsandpatientswithreducedkidneyandliverfunction,seesection4.2.

Useinchildrenandadolescentsunder18yearsofage

Antidepressantsshouldnotbeusedinthetreatmentofchildrenandadolescentsundertheageof18years.Suicide

relatedbehaviours(suicideattemptandsuicidalthoughts),andhostility(predominantlyaggression,oppositional

behaviourandanger)weremorefrequentlyobservedinclinicaltrialsamongchildrenandadolescentstreatedwith

antidepressantscomparedtothosetreatedwithplacebo.If,basedonclinicalneed,adecisiontotreatisnevertheless

taken,thepatientshouldbecarefullymonitoredfortheappearanceofsuicidalsymptoms.

Paradoxicalanxiety

Somepatientswithpanicdisordermayexperienceintensifiedanxietysymptomsatthestartoftreatmentwith

antidepressants.Thisparadoxicalreactionusuallysubsideswithinthefirsttwoweeksofstartingtreatment.Alow

startingdoseisadvisedtoreducethelikelihoodofaparadoxicalanxiogeniceffect(seesection4.2Posologyand

MethodofAdministration).

Hyponatraemia

Hyponatraemia,probablyduetoinappropriateantidiuretichormonesecretion(SIADH),hasbeenreportedasarare

adversereactionwiththeuseofSSRIs.Elderlyfemalepatientsespeciallyseemtobeariskgroup.

Suicide/suicidalthoughtsorclinicalworsening

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 2

riskpersistsuntilsignificantremissionoccurs.

Asimprovementmaynotoccurduringthefirstfewweeksormoreoftreatment,patientsshouldbecloselymonitored

untilsuchimprovementoccurs.Itisgeneralclinicalexperiencethattheriskofsuicidemayincreaseintheearlystages

ofrecovery.

Otherpsychiatricconditionsforwhichcitalopramisprescribedcanalsobeassociatedwithanincreasedriskofsuicide-

relatedevents.Inaddition,theseconditionsmaybeco-morbidwithmajordepressivedisorder.Thesameprecautions

observedwhentreatingpatientswithmajordepressivedisordershouldthereforebeobservedwhentreatingpatients

withotherpsychiatricdisorders.

Patientswithahistoryofsuicide-relatedevents,orthoseexhibitingasignificantdegreeofsuicidalideationpriorto

commencementoftreatment,areatgreaterriskofsuicidalthoughtsorsuicideattempts,andshouldreceivecareful

monitoringduringtreatment.Ameta-analysisofplacebo-controlledclinicaltrialsofantidepressantdrugsinadult

patientswithpsychiatricdisordersshowedanincreasedriskofsuicidalbehaviourwithantidepressantscomparedto

placeboinpatientslessthan25yearsold.

Closesupervisionofpatientsandinparticularthoseathighriskshouldaccompanydrugtherapyespeciallyinearly

treatmentandfollowingdosechanges.Patients(andcaregiversofpatients)shouldbealertedabouttheneedtomonitor

foranyclinicalworsening,suicidalbehaviourorthoughtsandunusualchangesinbehaviourandtoseekmedicaladvice

immediatelyifthesesymptomspresent.

Akathisia/psychomotorrestlessness

TheuseofSSRIs/SNRIshasbeenassociatedwiththedevelopmentofakathisia,characterisedbyasubjectively

unpleasantordistressingrestlessnessandneedtomoveoftenaccompaniedbyaninabilitytositorstandstill.Thisis

mostlikelytooccurwithinthefirstfewweeksoftreatment.Inpatientswhodevelopthesesymptoms,increasingthe

dosemaybedetrimental.

Mania

Inpatientswithmanic-depressiveillnessachangetowardsthemanicphasemayoccur.Shouldthepatiententera

manicphasecitalopramshouldbediscontinued.

Seizures

Althoughanimalexperimentshaveshownthatcitalopramhasnoepileptogenicpotentialitshould,likeother

antidepressants,beusedwithcautioninpatientswithahistoryofseizures.

Diabetes

Asdescribedforotherpsychotropicscitaloprammaymodifyinsulinandglucoseresponsescallingforadjustmentof

theantidiabetictherapyindiabeticpatients;inadditionthedepressiveillnessitselfmayaffectpatients´glucose

balance.

Serotoninsyndrome

Ifcitalopramisusedconcomitantlywithmedicinalproductswithserotonergiceffectssuchassumatriptanorother

triptans,tramadolandtryptophan,cautionisadvisable.

Rarely,theoccurrenceof“serotoninsyndrome”hasbeenreportedinpatientsreceivingSSRIs.Acombinationof

symptoms,possiblyincludingagitation,confusion,tremor,myoclonusandhyperthermia,mayindicatethe

developmentofthiscondition(seesection4.5Interactionwithothermedicinalproductsandotherformsofinteraction).

Haemorrhage

TherehavebeenreportsofcutaneousbleedingabnormalitiessuchasecchymosesandpurpurawithSSRIs.Cautionis

advisedinpatientstakingSSRIs,particularlywithconcomitantuseoforalanticoagulants;medicinalproductsknownto

affectplateletfunction(e.g.atypicalantipsychoticsandphenothiazines,mosttricyclicantidepressants,acetylsalicyclic

acidandnon-steroidalanti-inflammatorymedicinalproducts(NSAIDs),ticlopidineanddipyridamole)aswellasin

patientswithahistoryofbleedingdisorders(seesection4.5Interactionswithothermedicinalproductsandotherforms

ofinteraction).

ECT(electroconvulsivetherapy)

ThereislimitedclinicalexperienceofconcurrentadministrationofSSRIsandECT;thereforecautionisadvisable.

Reversible,selectiveMAO-Ainhibitors

ThecombinationofcitalopramwithMAO-Ainhibitorsisgenerallynotrecommendedduetotheriskofonsetofa

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 3

Forinformationonconcomitanttreatmentwithnon-selective,irreversibleMAO-inhibitors,seesection4.5.

StJohn'sWort

ConcomitantuseofSSRIsandherbalremediescontainingStJohn'sWort(Hypericumperforatum)mayresultinan

increasedincidenceofadversereactions(seesection4.5Interactionwithothermedicinalproductsandotherformsof

interaction).

WithdrawalsymptomsseenondiscontinuationofSSRItreatment

Withdrawalsymptomswhentreatmentisdiscontinuedarecommon,particularlyifdiscontinuationisabrupt(see

section4.8UndesirableEffects).Inarecurrencepreventionclinicaltrialwithcitalopram,adverseeventsafter

discontinuationofactivetreatmentwereseenin40%ofpatientsversus20%inpatientscontinuingcitalopram.

Theriskofwithdrawalsymptomsmaybedependentonseveralfactorsincludingthedurationanddoseoftherapyand

therateofdosereduction.Dizziness,sensorydisturbances(includingparaesthesia),sleepdisturbances(including

insomniaandintensedreams),agitationoranxiety,nauseaand/orvomiting,tremor,confusion,sweating,headache,

diarrhoea,palpitations,emotionalinstability,irritabilityandvisualdisturbancesarethemostcommonlyreported

reactions.Generallythesesymptomsaremildtomoderate,however,insomepatientstheymaybesevereinintensity.

Theyusuallyoccurwithinthefirstfewdaysofdiscontinuingtreatment,buttherehavebeenveryrarereportsofsuch

symptomsinpatientswhohaveinadvertentlymissedadose.

Generallythesesymptomsareself-limitingandusuallyresolvewithin2weeks,thoughinsomeindividualstheymay

beprolonged(2-3monthsormore).Itisthereforeadvisedthatcitalopramshouldbegraduallytaperedwhen

discontinuingtreatmentoveraperiodofseveralweeksormonths,accordingtothepatient'sneeds(seesection4.2

PosologyandMethodofAdministration).

Excipients

Thetabletscontainlactosemonohydrate.Patientswithrarehereditaryproblemsofgalactoseintolerance,theLapp

lactasedeficiencyorglucose-galactosemalabsorptionshouldnotreceivethismedicine.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Pharmacodynamicinteractions

Atthepharmacodynamicleveltherehaveonlybeenfewdocumentedcasesofserotoninsyndromewithcitalopramand

moclobemideandbuspirone.

Contraindicatedcombinations

MAOIs(non-selectiveaswellasselectiveA(moclobemide)-riskof“serotoninsyndrome”(seesection4.3

Contraindications).

Pimozide

Coadministrationofasingledoseofpimozide2mgtosubjectstreatedwithracemiccitalopram40mg/dayfor11days

causedanincreaseinAUCandC

ofpimozide,althoughnotconsistentlythroughoutthestudy.Theco-

administrationofpimozideandcitalopramresultedinameanincreaseintheQTcintervalofapproximately10msec.

Duetotheinteractionnotedatalowdoseofpimozide,concomitantadministrationofcitalopramandpimozideis

contraindicated.

Combinationsrequiringprecautionforuse

Selegiline(selectiveMAO-Binhibitor)

Apharmacokinetic/pharmacodynamicinteractionstudywithconcomitantlyadministeredcitalopram(20mgdaily)

andselegiline(10mgdaily)(aselectiveMAO-Binhibitor)demonstratednoclinicallyrelevantinteractions.Patients

toleratedtheselegiline-citalopramcombinationwell.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 4

Lithiumandtryptophan

Nopharmacodynamicinteractionshavebeenfoundinclinicalstudiesinwhichcitalopramhasbeengiven

concomitantlywithlithium.HowevertherehavebeenreportsofenhancedeffectswhenSSRIshavebeengivenwith

lithiumortryptophanandthereforetheconcomitantuseofcitalopramwiththesemedicinalproductsshouldbe

undertakenwithcaution.

Coadministrationwithserotonergicmedicinalproducts(e.g.tramadol,sumatriptan)mayleadtoenhancementof5-HT

associatedeffects.

St.John'sWort

DynamicinteractionsbetweenSSRIsandherbalremedyStJohn'swort(Hypericumperforatum)canoccur,resultingin

anincreaseinundesirableeffects(seesection4.4SpecialWarningsandPrecautionsforUse).

Haemorrhage

TherehavebeenreportsofcutaneousbleedingabnormalitiessuchasecchymosesandpurpurawithSSRIs.Cautionis

advisedinpatientstakingSSRIs,particularlywithconcomitantuseoforalanticoagulants;medicinalproductsknownto

affectplateletfunction(e.g.atypicalantipsychoticsandphenothiazines,mosttricyclicantidepressants,acetylsalicyclic

acidandnon-steroidalanti-inflammatorymedicinalproducts(NSAIDs),ticlopidineanddipyridamole)aswellasin

patientswithahistoryofbleedingdisorders(seesection4.4SpecialWarningsandPrecautionsforUse).

ECT(electroconvulsivetherapy)

Therearenoclinicalstudiesestablishingtherisksorbenefitsofthecombineduseofelectroconvulsivetherapy(ECT)

andcitalopram(seesection4.4SpecialWarningsandPrecautionsforUse).

Alcohol

ThecombinationofSSRIsandalcoholisnotadvisable.However,clinicalstudieshaverevealednoadverse

Pharmacodynamicinteractionsbetweencitalopramandalcohol.

Pharmacokineticinteractions

BiotransformationofcitalopramtodemethylcitalopramismediatedbyCYP2C19(approx.38%),CYP3A4(approx.

31%)andCYP2D6(approx.31%)isozymesofthecytochromeP450system.Thefactthatcitalopramismetabolisedby

morethanoneCYPmeansthatinhibitionofitsbiotransformationislesslikelyandco-administrationofcitalopram

withothermedicinalproductsinclinicalpracticehasverylowlikelihoodofproducingpharmacokineticmedicinal

productinteractions

Influenceofothermedicinalproductsonthepharmacokineticsofcitalopram

Co-administrationwithketoconazole(potentCYP3A4inhibitor)didnotchangethepharmacokineticsofcitalopram.A

pharmacokineticinteractionstudyoflithiumandcitalopramdidnotrevealanypharmacokineticinteractions.

Cimetidine(potentCYP2D6,3A4and1A2inhibitor)causedamoderateincreaseintheaveragesteadystatelevelsof

citalopram.Nogeneraldosereductionforcitalopramisrecommendedduringco-administrationwithcimetidine.

Effectsofcitalopramonothermedicinalproducts

Apharmacokinetic/pharmacodynamicinteractionstudywithconcomitantadministrationofcitalopramandmetoprolol

(aCYP2D6substrate)showedatwofoldincreaseinmetoprololconcentrations,butnostatisticallysignificantincrease

intheeffectofmetoprololonbloodpressureandheartrateinhealthyvolunteers.

CitalopramanddemethylcitalopramarenegligibleinhibitorsofCYP2C9,CYP2E1andCYP3A4,andonlyweak

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 5

Thusnochangeinpharmacokineticsoronlyverysmallchangesofnoclinicalimportancewereobservedwhen

citalopramwasgivenwithCYP1A2substrates(clozapineandtheophylline),CYP2C9(warfarin),CYP2C19

(imipramineandmephenytoin),CYP2D6(sparteine,imipramine,amitriptyline,risperidone)andCYP3A4(warfarin,

carbamazepineandtriazolam).

Inapharmacokineticinteractionstudycitalopramdidnotcauseanychangesinthepharmacokineticsofdigoxin

meaningthatcitalopramneitherinducesnorinhibitsP-glycoprotein.

4.6Fertility,pregnancyandlactation

Pregnancy

Clinicalexperienceofuseinpregnantwomenislimitedbutnoreports,whichmaycauseconcernhavebeenreceived.

Basedondatafromreproductiontoxicitystudies(segmentI,IIandIII)thereisnoreasontohavespecialconcernfor

theuseofcitalopraminwomenofchildbearingpotential.

NeonatesshouldbeobservedifmaternaluseofCipramilcontinuesintothelaterstagesofpregnancy,particularlyinthe

thirdtrimester.Abruptdiscontinuationshouldbeavoidedduringpregnancy.

ThefollowingsymptomsmayoccurintheneonatesaftermaternalSSRI/SNRIuseinlaterstagesofpregnancy:

respiratorydistress,cyanosis,apnoea,seizures,temperatureinstability,feedingdifficulty,vomiting,hypoglycaemia,

hypertonia,hypotonia,hyperreflexia,tremor,jitteriness,irritability,lethargy,constantcrying,somnolenceand

difficultysleeping.Thesesymptomscouldbeduetoeitherserotonergiceffectsordiscontinuationsymptoms.Ina

majorityofinstancesthecomplicationsbeginimmediatelyorsoon(<24hours)afterdelivery.

Lactation

Citalopramisexcretedintobreastmilk.Itisestimatedthatthesucklinginfantwillreceiveabout5%oftheweight

relatedmaternaldailydose(inmg/kg).Nooronlyminoreventshavebeenobservedintheinfants.However,the

existinginformationisinsufficientforassessmentoftherisktothechild.

Cautionisrecommended.

4.7Effectsonabilitytodriveandusemachines

Citalopramdoesnotimpairintellectualfunctionandpsychomotorperformance.However,patientswhoareprescribed

psychotropicmedicationmaybeexpectedtohavesomeimpairmentofgeneralattentionandconcentrationeitherdueto

theillnessitself,themedicationorbothandshouldbecautionedabouttheirabilitytodriveacarandoperate

machinery.

4.8Undesirableeffects

Adverseeffectsobservedwithcitalopramareingeneralmildandtransient.Theyaremostfrequentduringthefirstone

ortwoweeksoftreatmentandusuallyattenuatesubsequently.TheadversereactionsarepresentedattheMedDRA

PreferredTermLevel.

Forthefollowingreactionsadose-responsewasdiscovered:Sweatingincreased,drymouth,insomnia,somnolence,

diarrhoea,nauseaandfatigue.

ThetableshowsthepercentageofadversedrugreactionsassociatedwithSSRIsand/orcitalopramseenineither>1%

ofpatientsindouble-blindplacebo-controlledtrialsorinthepost-marketingperiod.Frequenciesaredefinedas:very

common(>1/10);common(>1/100,<1/10);uncommon(>1/1000,<1/100);rare(>1/10000,<1/1000);veryrare

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 6

MedDRASOC Frequency Preferredterm

Bloodandlymphatic

disorders NotKnown Thrombocytopenia

Immunesystem

disorders NotKnown Hypersensitivity,

Anaphylacticreaction

Endocrinedisorders NotKnown InappropriateADH

secretion

Metabolismand

nutritiondisorders Common Appetitedecreased

Uncommon Increasedappetite

Rare Hyponatraemia

Psychiatricdisorders Common Agitation,libido

decreased,anxiety,

nervousness,

confusionalstate,

abnormalorgasm

(female)

Uncommon Aggression,

depersonalization,

hallucination,mania

NotKnown Panicattack,bruxism,

restlessness,Suicide-

relatedevents(see

section4.4)

Nervoussystem

disorders Verycommon Somnolence,insomnia

Common Tremor,paraesthesia

Uncommon Syncope

Rare Convulsiongrandmal,

dyskinesia

NotKnown Convulsions,serotonin

syndrome,

extrapyramidal

disorder,akathisia,

movementdisorder

Eyedisorders Uncommon Mydriasis

NotKnown Visualdisturbance

Earandlabyrinth

disorders Common Tinnitus

Cardiacdisorders Uncommon Bradycardia,

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 7

Numberofpatients:Citalopram/placebo=1346/545

CasesofQT-prolongationhavebeenreportedduringthepost-marketingperiod,predominantlyinpatientswithpre-

Vasculardisorders NotKnown Orthostatic

hypotension

Respiratorythoracic

andmediastinal

disorders Common Yawning

NotKnown Epistaxis

Gastrointestinal

disorders Verycommon Drymouth,Nausea

Common Diarrhoea,vomiting

NotKnown Gastrointestinal

haemorrhage

(includingrectal

haemorrhage)

Hepatobiliary

disorders Rare Hepatitis

Skinandsubcutaneous

tissuedisorders Verycommon Sweatingincreased

Common Pruritus

Uncommon Urticaria,alopecia,

rash,purpura

NotKnown Ecchymosis,

angioedemas

Musculoskeletal,

connectivetissueand

bonedisorders Common Myalgia,arthralgia

Renalandurinary

disorders Uncommon Urinaryretention

Reproductivesystem

andbreastdisorders Common Impotence,ejaculation

disorder,ejaculation

failure

Uncommon Female:Menorrhagia

NotKnown Female:Metrorrhagia

Male:Priapism,

galactorrhoea

Generaldisordersand

administrationsite

conditions Common Fatigue

Uncommon Oedema

Investigations Common Weightdecreased

Uncommon Weightincreased

NotKnown Liverfunctiontest

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 8

WithdrawalsymptomsseenondiscontinuationofSSRItreatment

DiscontinuationofCitalopram(particularlywhenabrupt)commonlyleadstowithdrawalsymptoms.Dizziness,sensory

disturbances(includingparaesthesia),sleepdisturbances(includinginsomniaandintensedreams),agitationoranxiety,

nauseaand/orvomiting,tremor,confusion,sweating,headache,diarrhoea,palpitations,emotionalinstability,

irritability,andvisualdisturbancesarethemostcommonlyreportedreactions.Generallytheseeventsaremildto

moderateandareself-limiting,however,insomepatientstheymaybesevereand/orprolonged.Itisthereforeadvised

thatwhencitalopramtreatmentisnolongerrequired,gradualdiscontinuationbydosetaperingshouldbecarriedout

(seesection4.2andsection4.4).

4.9Overdose

Toxicity

Comprehensiveclinicaldataoncitalopramoverdosearelimitedandmanycasesinvolveconcomitantoverdosesof

otherdrugs/alcohol.Fatalcasesofcitalopramoverdosehavebeenreportedwithcitalopramalone;however,the

majorityoffatalcaseshaveinvolvedoverdosewithconcomitantmedications.

Symptoms

Thefollowingsymptomshavebeenseeninreportedoverdoseofcitalopram:convulsion,tachycardia,somnolence,QT

prolongation,coma,vomiting,tremor,hypotension,cardiacarrest,nausea,serotoninsyndrome,agitation,bradycardia,

dizziness,bundlebranchblock,QRSprolongation,hypertension,andmydriasis.

Treatment

Thereisnospecificantidote.Establishandmaintainanairway,ensureadequateoxygenationandrespiratoryfunction.

Gastriclavageandtheuseofactivatedcharcoalmightbeconsidered.Gastriclavageshouldbecarriedoutassoonas

possibleafteroralingestion.Cardiacandvitalsignsmonitoringarerecommendedalongwithgeneralsymptomatic

supportivemeasures.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

ATC-code:N06AB04

MechanismofAction

Biochemicalandbehaviouralstudieshaveshownthatcitalopramisapotentinhibitorofserotonin(5-HT)-uptake.

Tolerancetotheinhibitionof5-HT-uptakeisnotinducedbylong-termtreatmentwithcitalopram.

CitalopramisaverySelectiveSerotoninReuptakeInhibitor(SSRI)withno,orminimal,effectonnoradrenaline(NA),

dopamine(DA)andgammaaminobutyricacid(GABA)uptake.

IncontrasttomanytricyclicantidepressantsandsomeofthenewerSSRIs,citalopramhasnoorverylowaffinityfora

seriesofreceptorsincluding5-HT

5-HT

,DAD

andD

receptors,

-,-adrenoceptors,histamineH

muscarinecholinergic,benzodiazepine,andopioidreceptors.Aseriesoffunctionalinvitrotestsinisolatedorgansas

wellasfunctionalinvivotestshaveconfirmedthelackofreceptoraffinity.Thisabsenceofeffectsonreceptorscould

explainwhycitalopramproducesfewerofthetraditionalside-effectssuchasdrymouth,bladderandgutdisturbance,

blurredvision,sedation,cardiotoxicityandorthostatichypotension.

ThemainmetabolitesofcitalopramareallSSRIsalthoughtheirpotencyandselectivityratiosarelowerthanthoseof

citalopram.However,theselectivityratiosofthemetabolitesarehigherthanthoseofmanyofthenewerSSRIs.The

metabolitesdonotcontributetotheoverallantidepressanteffect.

Pharmacodynamiceffects

Suppressionofrapideyemovement(REM)sleepisconsideredapredictorofantidepressantactivity.Liketricyclic

antidepressants,otherSSRIsandMAOinhibitors,citalopramsuppressesREM-sleepandincreasesdeepslow-wave

sleep.

Althoughcitalopramdoesnotbindtoopioidreceptorsitpotentiatestheanti-nociceptiveeffectofcommonlyused

opioidanalgesics.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 9

minimalsedativeproperties,eitheraloneorincombinationwithalcohol.

Citalopramdidnotreducesalivaflowinasingledosestudyinhumanvolunteersandinnoneofthestudiesinhealthy

volunteersdidcitalopramhavesignificantinfluenceoncardiovascularparameters.Citalopramhasnoeffectonthe

serumlevelsofgrowthhormone.CitalopramlikeotherSSRIsmayincreaseplasmaprolactin,aneffectsecondarytothe

prolactinstimulatingroleofserotoninandofnoclinicalimportance.

5.2Pharmacokineticproperties

Absorption

Absorptionisalmostcompleteandindependentoffoodintake(T

mean3hours).Oralbioavailabilityisabout80%.

Distribution

Theapparentvolumeofdistribution(V

)isabout12-17L/kg.Theplasmaproteinbindingisbelow80%for

citalopramanditsmainmetabolites.

Biotransformation

Citalopramismetabolisedtotheactivedemethylcitalopram,didemethylcitalopram,citalopram-N-oxideandaninactive

deaminatedpropionicacidderivative.AlltheactivemetabolitesarealsoSSRIs,althoughweakerthantheparent

compound.Unchangedcitalopramisthepredominantcompoundinplasma.Theconcentrationsofdemethylcitalopram

anddidemethylcitalopramareusually30-50%and5-10%ofthecitalopramconcentration,respectively.The

biotransformationofcitalopramtodemethylcitalopramismediatedbyCYP2C19(approx.38%),CYP3A4(approx.

31%)andCYP2D6(approx.31%).

Elimination

Theeliminationhalf-life(T

)isabout1.5daysandthesystemiccitalopramplasmaclearance(Cl

)isabout0.3-0.4

L/min,andoralplasmaclearance(Cl

oral )isabout0.4L/min.

Citalopramisexcretedmainlyviatheliver(85%)andtheremainder(15%)viathekidneys;12%-23%ofthedaily

doseisexcretedinurineasunchangedcitalopram.Hepatic(residual)clearanceisabout0.3L/minandrenalclearance

about0.05-0.08L/min.

Linearity

Thekineticsarelinear.Steadystateplasmalevelsareachievedin1-2weeks.Averageconcentrationsof300nmol/L

(165-405nmol/L)areachievedatadailydoseof40mg.

Elderlypatients(>65years)

Longerhalf-lives(1.5-3.75days)anddecreasedclearancevalues(0.08-0.3L/min)duetoareducedrateofmetabolism

havebeendemonstratedinelderlypatients.Steadystatevalueswereabouttwiceashighintheelderlyasinyounger

patientstreatedwiththesamedose.

Reducedhepaticfunction

Citalopramiseliminatedmoreslowlyinpatientswithreducedhepaticfunction.Thehalf-lifeofcitalopramisabout

twiceaslongandsteadystatecitalopramconcentrationsatagivendosewillbeabouttwiceashighasinpatientswith

normalliverfunction.

Reducedrenalfunction

Citalopramiseliminatedmoreslowlyinpatientswithmildtomoderatereductionofrenalfunction,withoutanymajor

impactonthepharmacokineticsofcitalopram.Atpresentnoinformationisavailablefortreatmentofpatientswith

severelyreducedrenalfunction(creatinineclearance<20mL/min).

Polymorphism

Invivoinvestigationshaveshownthatthemetabolismofcitalopramexhibitsnoclinicallyimportantpolymorphismof

thesparteine/debrisoquineoxidation(CYP2D6).ForCYP2C19,asaprecaution,aninitialdoseof10mgshouldbe

consideredforknownpoormetabolisers(seesection4.2).

Pharmacokinetic/pharmacodynamicrelationship

Thereisnoclearrelationshipbetweencitalopramplasmalevelsandtherapeuticresponseorsideeffects.The

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 10

5.3Preclinicalsafetydata

Acutetoxicity

Citalopramhaslowacutetoxicity.

Chronictoxicity

Inchronictoxicitystudiestherewerenofindingsofconcernforthetherapeuticuseofcitalopram.

Reproductionstudies

Basedondatafromreproductiontoxicitystudies(segmentI,IIandIII)thereisnoreasontohavespecialconcernfor

theuseofcitalopraminwomenofchildbearingpotential.

Citalopramappearsinmilkinlowconcentrations.

Embryotoxicitystudiesinratswithdosesof56mg/kg/day,whichcausematernaltoxicityshowedboneanomaliesin

theregionofthevertebralcolumnandribs.Thematernalplasmalevelwasthen2-3timesthetherapeuticconcentration

inman.Inratscitalopramdidnothaveanyeffectonfertility,pregnancyandpostnataldevelopmentbutdiminishedthe

birthweightofthepups.Citalopramanditsmetabolitesreachfoetalconcentrations,whichare10-15timesthematernal

plasmalevel.Clinicalexperienceofuseinpregnantwomenandduringlactationislimited.

Mutagenicandcarcinogenicpotential

Citalopramhasnomutagenicorcarcinogenicpotential.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Maizestarch

Lactosemonohydrate

Microcrystallinecellulose

Copovidone

Glycerol(85%)(E422)

Croscarmellosesodium

Magnesiumstearate

Hypromellose

Macrogol400

Titaniumdioxide(E171)

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Theshelflifeexpirydateofthisproductshallbethedateshownonthecontainerandouterpackageoftheproducton

themarketinthecountryoforigin.

6.4Specialprecautionsforstorage

Donotstoreabove25 °

6.5Natureandcontentsofcontainer

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 11

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7PARALLELPRODUCTAUTHORISATIONHOLDER

PCOManufacturing

Unit10,AshbourneBusinessPark

Rath

Ashbourne

Co.Meath

8PARALLELPRODUCTAUTHORISATIONNUMBER

PPA0465/068/001

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:24July2001

Dateoflastrenewal:24July2006

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 27/06/2011 CRN 2101974 page number: 12